Clinical trials: Moderate and Severe Active Rheumatoid Arthritis
- Condition Moderate and Severe Active Rheumatoid Arthritis
- Funder type Industry (pharma, biotech, devices)
Rheumatoid Arthritis
A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis
Rheumatoid Arthritis (RA) is a chronic inflammatory disease causing pain, stiffness, swelling and loss of joint function. This study will evaluate the efficacy and safety of targeted therapies through a series of substudies for…
- Trial name
- NCT06972446
- Testing
- Lutikizumab, Ravagalimab
- Where
- 96 sites in United States, Canada and 10 more
- Volunteers
- 180 people
- Sponsor
- AbbVie
Active, Moderate to Severe Rheumatoid Arthritis
A Randomized, Double-blind, Placebo-controlled Clinical Study of the Oral IL-12/23 Inhibitor, STA-5326 Mesylate, Administered to Patients With Rheumatoid Arthritis to Determine Safety, Tolerability, Pharmacokinetic and Synovial Tissue Outcomes
It is not fully clear how rheumatoid arthritis originates and develops, but it is understood that multiple genetic and environmental factors interact to trigger its onset.
- Trial name
- NCT00642629
- Testing
- STA 5326 mesylate
- Where
- Netherlands
- Volunteers
- 35 people
- Sponsor
- Synta Pharmaceuticals Corp.
Arthritis, Rheumatoid
Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate
This study [contRAst 1 (201790: NCT03980483)] is a phase 3, randomized, multicenter, double blind study to assess the safety and efficacy of GSK3196165, in combination with methotrexate (MTX), for the treatment of adult…
- Trial name
- contRAst 1 (NCT03980483)
- Testing
- GSK3196165 (Otilimab), Tofacitinib 5 mg
- Where
- 76 sites in China, Hungary and 8 more
- Volunteers
- 1,537 people
- Sponsor
- GlaxoSmithKline
Rheumatoid Arthritis
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate (MTX) in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One Tumor Necrosis Factor (TNF)-Inhibitor
This randomized, parallel-group study will assess the efficacy and safety of RoActemra/Actemra (tocilizumab) versus adalimumab, both in combination with methotrexate (MTX) in patients with moderate to severe active rheumatoid…
- Trial name
- NCT01283971
- Testing
- tocilizumab [RoActemra/Actemra], adalimumab, methotrexate
- Where
- 170 sites in United States, Denmark and 10 more
- Volunteers
- 96 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
A Study to Determine the Effect of Methotrexate (MTX) Dose on Clinical Outcome and Ultrasonographic Signs in Subjects With Moderately to Severely Active Rheumatoid Arthritis (RA) Treated With Adalimumab (MUSICA)
This study will investigate the efficacy of both low and high doses of methotrexate (MTX) in combination with open-label adalimumab (ADA) in patients who have had an inadequate response to high dose of MTX.
- Trial name
- MUSICA (NCT01185288)
- Testing
- Adalimumab, Methotrexate
- Where
- 49 sites in United States, Puerto Rico
- Volunteers
- 309 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Rhematoid Arthritis
An Efficacy And Safety Study Evaluating Tofacitinib With And Without Methotrexate Compared To Adalimumab With Methotrexate
To assess the efficacy of tofacitinib monotherapy or tofacitinib with methotrexate as compared to adalimumab with methotrexate. To compare the efficacy of tofacitinib monotherapy compared to tofacitinib combined with…
- Trial name
- ORAL STRATEGY (NCT02187055)
- Testing
- Tofacitinib with methotrexate, Tofacitinib without methotrexate, Adalimumab with methotrexate
- Where
- 215 sites in United States, Argentina and 23 more
- Volunteers
- 1,152 people
- Sponsor
- Pfizer
Rheumatoid Arthritis
Study to Describe Real World Drug Retention Rate of the Tocilizumab at One Year
This multicenter, prospective, non-interventional study is designed to obtain an accurate estimation of the drug retention rate of Tocilizumab (TCZ) Subcutaneously (SC) under real-world conditions in participants with moderate to…
- Trial name
- NCT02608112
- Testing
- Methotrexate, Tocilizumab
- Where
- 77 sites in France
- Volunteers
- 291 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
A Study to Assess the Effect of Tocilizumab Plus Methotrexate on Safety and Signs and Symptoms in Patients With Moderate to Severe Active Rheumatoid Arthritis
This single arm, open-label study will assess the safety and efficacy with regar d to reduction of signs and symptoms of treatment with tocilizumab in combinatio n with methotrexate, in patients with moderate to severe active…
- Trial name
- NCT00754572
- Testing
- tocilizumab [RoActemra/Actemra], methotrexate
- Where
- 69 sites in Argentina, Brazil and 8 more
- Volunteers
- 418 people
- Sponsor
- Hoffmann-La Roche
Moderate and Severe Active Rheumatoid Arthritis, Active Psoriatic Arthritis
Study to Test the Safe and Effective Use of an e-Device for the Self-injection of Certolizumab Pegol Solution by Subjects With Moderate to Severe Active Rheumatoid Arthritis, Active Ankylosing Spondylitis, Active Psoriatic Arthritis, or Moderately to Severely Active Crohn's Disease
The purpose of the study is to evaluate the ability of subjects who are already prescribed Certolizumab Pergol therapy and have been self injecting with prefilled syringes for at least the previous three months, to safely and…
- Conditions
- Moderate and Severe Active Rheumatoid Arthritis, Active Psoriatic Arthritis, Active Ankylosing Spondylitis, Moderately to Severely Active Crohn's Disease
- Trial name
- NCT03357471
- Testing
- e-Device
- Where
- 22 sites in United States
- Volunteers
- 70 people
- Sponsor
- UCB Biopharma S.P.R.L.
Rheumatoid Arthritis
A Study of Tocilizumab With or Without Methotrexate in Patients With Rheumatoid Arthritis.
This open-label, single-arm, non-randomized study will evaluate the adherence and persistence to tocilizumab therapy in patients with moderate to severe active rheumatoid arthritis, who have an inadequate clinical response to…
- Trial name
- NCT01010503
- Testing
- tocilizumab [RoActemra/Actemra]
- Where
- Slovakia
- Volunteers
- 32 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
To Evaluate 1 Year Extension Study of the Efficacy and Safety of Tocilizumab in Patients With Moderate to Severe Rheumatoid Arthritis
The purpose of this study is to evaluate 1 year extension study of the efficacy and the safety during treatment tocilizumab in patients completing treatment CWP-TCZ301 study with moderate to severe active RA and an inadequate…
- Trial name
- NCT01256736
- Testing
- Tocilizumab, DMARDs
- Where
- South Korea
- Volunteers
- 89 people
- Sponsor
- JW Pharmaceutical
Rheumatoid Arthritis
TO ASSESS THE EFFICACY AND SAFETY OF PF-06650833, PF-06651600, AND TOFACITINIB ALONE AND IN COMBINATION IN PARTICIPANTS WITH ACTIVE RHEUMATOID ARTHRITIS WITH AN INADEQUATE RESPONSE TO METHOTREXATE
Dual objectives of increased efficacy compared to currently available SoC RA drugs and maintaining a favourable benefit - risk relationship.
- Trial name
- NCT04413617
- Testing
- PF-06650833, PF-06651600, Tofacitinib
- Where
- 144 sites in Bulgaria, Canada and 8 more
- Volunteers
- 460 people
- Sponsor
- Pfizer
Rheumatoid Arthritis
A Study in Participants With Moderate to Severe Rheumatoid Arthritis
The purpose of this study is to determine whether baricitinib therapy alone is noninferior to methotrexate (MTX) therapy alone in the treatment of moderate to severe active rheumatoid arthritis (RA) in those who have had limited…
- Trial name
- RA-BEGIN (NCT01711359)
- Testing
- Baricitinib, Methotrexate, Folic Acid
- Where
- 154 sites in United States, Argentina and 17 more
- Volunteers
- 588 people
- Sponsor
- Eli Lilly and Company
RA
To Evaluate Sarilumab - SAR153191 (REGN88) - Auto-injector Device In Patients With Rheumatoid Arthritis
Primary Objective: To collect real-use data of the sarilumab auto-injector device (AID) used by rheumatoid arthritis (RA) participants.
- Trial name
- SARIL-RA-EASY (NCT02057250)
- Testing
- Sarilumab, Auto-Injector Device (AID), Pre-filled Syringe (PFS)
- Where
- 53 sites in United States, Chile and 4 more
- Volunteers
- 217 people
- Sponsor
- Sanofi
Arthritis, Rheumatoid
Evaluation of Pharmacokinetics and Safety of GSK3196165 in Combination With Methotrexate in Japanese Subjects With Rheumatoid Arthritis
This is a randomized, double-blind, parallel group, 3 dosage level, placebo-controlled, Phase 1/2 study designed to evaluate the pharmacokinetics, safety, tolerability, and efficacy of the monoclonal antibody GSK3196165, in…
- Trial name
- NCT03028467
- Testing
- GSK3196165 Dose 1, GSK3196165 Dose 2, GSK3196165 Dose 3
- Where
- 32 sites in Japan
- Volunteers
- 15 people
- Sponsor
- GlaxoSmithKline
Arthritis, Rheumatoid
Efficacy and Safety of GSK3196165 (Otilimab) Versus Placebo and Sarilumab in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biological Disease-modifying Antirheumatic Drug (DMARDs) and/or Janus Kinase (JAK) Inhibitors
This study (contRAst 3 [202018: NCT04134728]) is a Phase 3, randomized, multicenter, double-blind study to assess the safety and efficacy of GSK3196165 in combination with conventional (cs) DMARD[s]) or the treatment of adult…
- Trial name
- contRAst 3 (NCT04134728)
- Testing
- GSK3196165 (Otilimab), Sarilumab, csDMARDs
- Where
- 131 sites in United States, Argentina and 13 more
- Volunteers
- 550 people
- Sponsor
- GlaxoSmithKline
Rheumatoid Arthritis
Filgotinib Alone and in Combination With Methotrexate (MTX) in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Are Naive to MTX Therapy
The primary objective of this study is to evaluate the effects of filgotinib in combination with methotrexate (MTX) versus MTX alone in adults with active rheumatoid arthritis (RA).
- Trial name
- FINCH 3 (NCT02886728)
- Testing
- Filgotinib, MTX
- Where
- 186 sites in United States, Argentina and 29 more
- Volunteers
- 1,252 people
- Sponsor
- Gilead Sciences
Rheumatoid Arthritis
Study Evaluating Gerilimzumab´s Safety/Efficacy for Patients MTX or TNFα Antagonist Failed in Rheumatoid Arthritis
Phase 2 Study Evaluating Gerilimzumab's Safety/Efficacy for Patients with an Inadequate Response to MTX or a TNFα Antagonist in Rheumatoid Arthritis.
- Trial name
- NCT02795299
- Testing
- Gerilimzumab, Methotrexate, Folic Acid
- Sponsor
- Bird Rock Bio, Inc.
Rheumatoid Arthritis
Good EULAR Response In Patients With Early Rheumatoid Arthritis
This open-label, prospective, observational study will evaluate the clinical response to etanercept + methotrexate therapy in patients with moderate to severe rheumatoid arthritis, as prescribed by the rheumatologist in a normal…
- Trial name
- EARLY RA (NCT01558089)
- Testing
- etanercept, methotrexate
- Where
- 9 sites in Greece
- Volunteers
- 76 people
- Sponsor
- Pfizer
Rheumatoid Arthritis
A Study Assessing the Safety and Efficacy of Subcutaneous RoActemra/Actemra Alone or in Combination With Non-biologic Antirheumatics in Rhuematoid Arthritis Patients in Latin America With Inadequate Response to Non-biologic Antirheumatic Drugs.
This multi-center, open-label, single-arm, Phase IIIb study will evaluate the safety and efficacy of subcutaneous RoActemra/Actemra alone or in combination with non-biologic disease modifying antirheumatic drugs (DMARDs) in…
- Trial name
- NCT02011334
- Testing
- tocilizumab [RoActemra/Actemra]
- Where
- 25 sites in Argentina, Brazil and 4 more
- Volunteers
- 285 people
- Sponsor
- Hoffmann-La Roche